Skip to content

Author

C. E. Caldon

We have 2 of 73 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A056: Targeting the mutant p53 cancer cell secretome sensitizes tumors to gemcitabine/nab-paclitaxel chemotherapy and reduces metastasis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...

Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al. · 0 citations
Open access Aug 2026

MDM2 inhibition restores p53 function to overcome dual endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer

The case for clinical evaluation of MDM2 inhibition in this setting of urgent clinical need is supported, as NVP-CGM097 demonstrates single agent efficacy in dual-resistant ER+ breast cancer through G 1 arrest and senescence.

Leila Eshraghi, Fiona H. Zhou, Sarah Alexandrou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.